SI-BONE, Inc. (SIBN) Fair Value 2026

SIBN · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.5 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (6/100)

Quick Summary — As of 2026-08-28, SI-BONE, Inc. (SIBN) trades at $19.21. QOC: 7.5/10. Value Trap Risk: 6/100 (SAFE). 0/13 models active.

Key Facts

Ticker
SIBN
Price
$19.21
Quality Score
7.5/10
Value Trap Risk
6/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give SIBN?

0 Intrinsic Value Models vs. Current Price ($19.21)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is SI-BONE, Inc. (SIBN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, SI-BONE, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About SIBN?

0 of 13 models are currently active for SIBN. See which stocks rank higher →

How Does SIBN Rank in Medical Devices?

Among 159 Medical Devices stocks, SIBN ranks #35 by Quality of Company score. CirclFi's QOC score of 7.5/10 evaluates 32 fundamental signals. A score of 7.5 indicates above-average quality.

See all Most Undervalued Medical Devices Stocks →

The Medical Devices sector introduces analytical considerations specific to pharmaceutical industry businesses. For SI-BONE, Inc., metrics like FDA approval probability provide important context that general-purpose valuation models may underweight.

Is SIBN a Value Trap?

CirclFi's Value Trap algorithm assigns SIBN a score of 6/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for SI-BONE, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, SI-BONE, Inc. scores 7.5 out of 10 on our 32-signal quality assessment, a strong rating that demonstrates strong fundamentals across the majority of our quality signals. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SIBN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy SI-BONE, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

BRKRBruker CorporationQOC 7.5DCTHDelcath Systems, Inc.QOC 7.4AXGNAxogen, Inc.QOC 7.6SNWVSANUWAVE Health, Inc.QOC 7.4BIOBio-Rad Laboratories, Inc.QOC 7.8VREXVarex Imaging CorporationQOC 7.3ARAYAccuray IncorporatedQOC 6.4GTHPGuided Therapeutics, Inc.QOC 5.5RTGNRetinalGenix Technologies Inc.QOC 3.5IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: BRKR · DCTH · AXGN · SNWV · BIO · VREX · ARAY · GTHP · RTGN · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to SIBN?

7 companies across all industries closest to SIBN’s Quality of Company score of 7.5/10.

MICCThe Magnum Ice Cream Company N.V.QOC 7.5SUNBSunbelt Rentals Holdings, Inc.QOC 7.5RLJRLJ Lodging TrustQOC 7.5NOKNokia OyjQOC 7.5SGISomnigroup International Inc.QOC 7.5FSBWFS Bancorp, Inc.QOC 7.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: MICC · SUNB · RLJ · NOK · SGI · FSBW · NVDA

Where Does SIBN Sit in CirclFi's Medical Devices Rankings?

SIBN is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About SI-BONE, Inc.’s Valuation?

What is SI-BONE, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for SI-BONE, Inc. (SIBN). The Quality of Company score is 7.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SIBN overvalued or undervalued right now?

At $19.21, 0 of 0 active models suggest SIBN may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits SI-BONE, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 7.5 mean for SIBN?

SI-BONE, Inc.'s QOC of 7.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on SIBN?

CirclFi analyzes SIBN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is SIBN a value trap in 2026?

SI-BONE, Inc.'s Value Trap score is 6/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns SI-BONE, Inc. (SIBN) a Quality of Company score of 7.5/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/SIBN/ · Methodology
Primary sources for this SIBN valuation
  • Financial statements: SI-BONE, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001459839) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SIBN as of ; valuations recomputed .